Medical Devices

IDEAYA Biosciences begins a key trial for its targeted therapy IDE892, aiming to conquer hard-to-treat tumors and pivoting to focus on its proprietary assets.

An in-depth look at the Nooro foot massager reveals a gap between its marketing claims, FDA clearance, and a pattern of customer service complaints.

Amid rising avian flu concerns, Canada secures millions of next-gen cell-based vaccines, upgrading its pandemic response arsenal for faster protection.

Eli Lilly and the WHO Foundation have launched a new collaboration to strengthen health systems and combat the escalating obesity crisis in underserved regions.

French pharma giant Servier acquires Day One Biopharmaceuticals, gaining a breakthrough pediatric cancer drug and signaling a major push into rare oncology.

Dr. Pietro Garbelli's award-winning book offers a crucial roadmap for responsibly integrating AI, balancing high-tech innovation with patient trust.

A landmark court decision certifies a massive class action against Johnson & Johnson, alleging its Baby Powder caused cancer and the company misled consumers.

The U.S. Army Medical Department's top-tier partnership with nurse anesthetists signals a new era for military healthcare readiness and professional recognition.

A new drug for Raynaud's phenomenon in scleroderma patients significantly boosts attack-free days, offering hope despite missing its primary trial goal.

Allarity Therapeutics lands a crucial $20M debt deal to push its unique ovarian cancer drug, stenoparib, through late-stage trials and extend its runway to 2028.

NeuroPace will present its RNS System at the Leerink conference, a key moment for the company to showcase its epilepsy treatment to top investors.

NextCure accelerates its high-stakes ovarian cancer drug trial, but with cash dwindling, can it reach the finish line before time runs out?

As Hyperfine preps its 2025 results, investors and clinicians watch to see if its portable Swoop MRI can translate clinical promise into financial success.

With a strong cash position, ArriVent pushes its lead lung cancer drug toward a mid-2026 data readout while building a new pipeline in ADCs.

VIO Med Spa is using an advanced training university to standardize excellence, drive rapid franchise growth, and define the future of aesthetic medicine.

With a new SVP of Global Sales, Slingshot Biosciences is poised to scale its synthetic cell mimic technology, targeting the booming cell therapy market.

Sarah Sommer, a deaf digital marketing exec, joins the Oberkotter Foundation board, blending personal insight with corporate strategy to advance hearing healthcare.

With data from 150M patients, SEQSTER's new platform promises to accelerate drug development, improve trial diversity, and make research-ready data a reality.

As burnout plagues radiology, Fujifilm unveils AI workflow solutions at HIMSS 2026 aimed at easing workloads and boosting hospital efficiency.

The biotech firm accelerates a key trial but faces a partner loss, widening losses, and a CEO search, putting its promising siRNA pipeline at a crossroads.